PLK1 and small cell lung carcinoma: Although PLK1 inhibitors showed potent in vitro activity at nanomolar concentrations against SCLC cell lines, there were differences in the IC50 concentrations between cell lines at the extremes of sensitivity (Figure 1b,c; Table 1).